Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome

Area of Science:

• Cardiology
• Nephrology
• Endocrinology

Background:

• Heart failure (HF) prevalence is rising, with distinct forms like diastolic HF (preserved LVEF) and systolic HF (reduced LVEF).
• Advanced glycation end-products (AGEs) accumulate with aging, diabetes, and renal failure.
• AGEs are implicated in collagen crosslinking, fibrosis, and impaired calcium handling, contributing to diastolic and renal dysfunction.

Purpose of the Study:

• To review the pathophysiological role of AGEs in linking heart and renal failure.
• To explore AGEs as a potential factor in the development and progression of diastolic HF and renal failure.
• To discuss the therapeutic potential of AGE intervention in HF patients.

Main Methods:

• Literature review focusing on the pathophysiological mechanisms of AGEs.
• Analysis of studies linking AGE accumulation to diastolic dysfunction and renal impairment.
• Exploration of potential AGE-modulating treatments for heart failure.

Main Results:

• AGE accumulation is associated with diastolic dysfunction, a common issue in elderly, diabetic, and renal failure patients.
• AGEs contribute to fibrosis and impaired calcium handling, exacerbating both heart and kidney dysfunction.
• A strong link exists between AGEs, diastolic HF, and progressive renal failure.

Conclusions:

• AGEs represent a significant pathophysiological link between heart and renal failure.
• Targeting AGEs may be a promising therapeutic avenue for managing diastolic heart failure.
• Further research into AGE intervention is warranted for HF treatment strategies.